nach oben

Current Cardiovascular Imaging Reports

Erschienen in:

01.07.2018 | Molecular Imaging (J Wu and PK Nguyen, Section Editors)

Molecular Imaging of Cardiac Amyloidosis

verfasst von: Sarah Cuddy, Rodney Falk, Sharmila Dorbala

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cardiac amyloidosis is an infiltrative cardiomyopathy, most commonly due to light chain amyloidosis [AL] or transthyretin amyloidosis [ATTR]; both cause significant heart failure and mortality. This review is a comprehensive overview of radionuclide molecular imaging in cardiac amyloidosis, highlighting the latest advancements in aiding diagnosis and prognosis.

Recent Findings

Specific bone scintigraphy agents have a high sensitivity and specificity for the diagnosis of transthyretin cardiac amyloidosis. Amyloid-binding radiotracers, originally developed for imaging Alzheimer’s disease, are being employed to image light chain and transthyretin cardiac amyloidosis. There is ongoing research into the use of these tracers for precise quantification of cardiac amyloidosis, which can be used to guide therapy.

Summary

Radionuclide molecular imaging techniques have a vital role in advancing the field of cardiac amyloidosis. With a broadening armamentarium of novel radio tracers and new therapeutic developments, this is an exciting area, with potential breakthroughs on the horizon.

Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047–60. https://doi.org/10.1161/CIRCULATIONAHA.104.489187.CrossRefPubMed

Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–300. https://doi.org/10.1161/CIRCULATIONAHA.111.078915.CrossRefPubMedPubMedCentral

Alexander KM, Singh A, Falk RH. Novel pharmacotherapies for cardiac amyloidosis. Pharmacol Ther. 2017;180:129–38. https://doi.org/10.1016/j.pharmthera.2017.06.011.CrossRefPubMed

Dorbala S, Kijewski MF, Park MA. Quantitative molecular imaging of cardiac amyloidosis: the journey has begun. J Nucl Cardiol. 2015;23:751–3. https://doi.org/10.1007/s12350-015-0235-z.CrossRefPubMed

Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014;7(3):552–62. https://doi.org/10.1161/CIRCIMAGING.113.001396.

Bravo PE, Dorbala S. Targeted nuclear imaging probes for cardiac amyloidosis. Curr Cardiol Rep. 2017;19(7):59. https://doi.org/10.1007/s11886-017-0868-4.

Dorbala Sharmila, Bokhari Sabahat, Miller Edward, Bullock-Palmer Renee, Soman Prem, Thompson Randall. 2016. ASNC Practice Points: 99mTechnetium-Pyrophosphate Imaging for Transthyretin Cardiac Amyloidosis. Online: American Society of Nuclear Cardiology. https://www.asnc.org/Files/Practice%20Resources/Practice%20Points/ASNC%20Practice%20Point-99mTechnetiumPyrophosphateImaging2016.pdf. Accessed August 17 2017

Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol. 1979;38(2):284–93.PubMedPubMedCentral

Bokhari S, Shahzad R, Maurer M. Radionuclide imaging in cardiac amyloidosis: are nuclear bone tracers a foreseeable future? Current Cardiovascular Imaging Reports. 2015;8(3). doi:https://doi.org/10.1007/s12410-015-9344-y.

10.

• Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12. https://doi.org/10.1161/CIRCULATIONAHA.116.021612. This is the largest experience to date compiling data from multiple centers and showing the high accuracy of bone imaging in the diagnosis of ATTR cardiac amyloidosis CrossRefPubMed

11.

Lee VW, Caldarone AG, Falk RH, Rubinow A, Cohen AS. Amyloidosis of heart and liver: comparison of Tc-99m pyrophosphate and Tc-99m methylene diphosphonate for detection. Radiology. 1983;148(1):239–42. https://doi.org/10.1148/radiology.148.1.6304810.CrossRefPubMed

12.

Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201. https://doi.org/10.1161/CIRCIMAGING.112.000132.CrossRefPubMedPubMedCentral

13.

Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880–9. https://doi.org/10.1001/jamacardio.2016.2839.CrossRefPubMed

14.

Sperry BW, Vranian MN, Tower-Rader A, Hachamovitch R, Hanna M, Brunken R, et al. Regional variation in technetium pyrophosphate uptake in transthyretin cardiac amyloidosis and impact on mortality. J Am Coll Cardiol Img. 2018;11(2 Pt 1):234–42. https://doi.org/10.1016/j.jcmg.2017.06.020.CrossRef

15.

Castano A, DeLuca A, Weinberg R, Pozniakoff T, Blaner WS, Pirmohamed A, et al. Serial scanning with technetium pyrophosphate ((99m)Tc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol. 2016;23(6):1355–63. https://doi.org/10.1007/s12350-015-0261-x.CrossRefPubMed

16.

Gagliardi C, Tabacchi E, Bonfiglioli R, Diodato S, Nanni C, Guidalotti P, et al. Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT? J Nucl Cardiol. 2016;24:746–9. https://doi.org/10.1007/s12350-016-0457-8.CrossRefPubMed

17.

Van Der Gucht A, Galat A, Rosso J, Guellich A, Garot J, Bodez D, et al. [18F]-NaF PET/CT imaging in cardiac amyloidosis. J Nucl Cardiol. 2016;23(4):846–9. https://doi.org/10.1007/s12350-015-0287-0.CrossRef

18.

Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S. (18)Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2017; https://doi.org/10.1007/s12350-017-0799-x.

19.

Noordzij W, Glaudemans AW, van Rheenen RW, Hazenberg BP, Tio RA, Dierckx RA, et al. (123)I-labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging. 2012;39(10):1609–17. https://doi.org/10.1007/s00259-012-2187-8.CrossRefPubMedPubMedCentral

20.

Trivieri MG, Dweck MR, Abgral R, Robson PM, Karakatsanis NA, Lala A, et al. (18)F-sodium fluoride PET/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol. 2016;68(24):2712–4. https://doi.org/10.1016/j.jacc.2016.09.953.CrossRefPubMedPubMedCentral

21.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55(3):306–19. https://doi.org/10.1002/ana.20009.CrossRefPubMed

22.

• Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot study. J Nucl Med. 2016;57:1733–9. https://doi.org/10.2967/jnumed.115.169870. This was the first publication to show the value of 18F-florbetaben to image cardiac amyloidosis.CrossRefPubMed

23.

• Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using (18)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652–62. https://doi.org/10.1007/s00259-014-2787-6. This was the first publication to show the value of 18F-florbetapir to image cardiac amyloidosis CrossRefPubMed

24.

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319–29. https://doi.org/10.1002/ana.22068.CrossRefPubMed

25.

Svedberg MM, Hall H, Hellstrom-Lindahl E, Estrada S, Guan Z, Nordberg A, et al. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int. 2009;54(5–6):347–57. https://doi.org/10.1016/j.neuint.2008.12.016.CrossRefPubMed

26.

• Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54(2):213–20. https://doi.org/10.2967/jnumed.111.102053. This was the first publication showing the value of 11C-PIB to image cardiac amyloidosis CrossRefPubMed

27.

• Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, et al. (11)C-Pittsburgh B PET imaging in cardiac amyloidosis. J Am Coll Cardiol Img. 2015;8(1):50–9. https://doi.org/10.1016/j.jcmg.2014.09.018. This was the first publication showing differences in 11C-PIB uptake among patients with and without prior chemotherapy CrossRef

28.

Kero T, Lindsjo L, Sorensen J, Lubberink M. Accurate analysis and visualization of cardiac (11)C-PIB uptake in amyloidosis with semiautomatic software. J Nucl Cardiol. 2016;23(4):741–50. https://doi.org/10.1007/s12350-015-0149-9.CrossRefPubMed

29.

Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent—a pilot study. Nucl Med Biol. 2010;37(4):497–508. https://doi.org/10.1016/j.nucmedbio.2010.02.003.CrossRefPubMed

30.

Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275–83. https://doi.org/10.1001/jama.2010.2008.CrossRefPubMed

31.

• Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veeranna V et al. 18F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circulation Cardiovascular Imaging. 2015;8(8). doi:https://doi.org/10.1161/CIRCIMAGING.114.002954. This was the first publication demonstrating specific binding of 18F-florbetapir to myocardial AL and ATTR deposits.

32.

Hawkins PN, Aprile C, Capri G, Vigano L, Munzone E, Gianni L, et al. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med. 1998;25(7):701–8.CrossRefPubMed

33.

Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323(8):508–13. https://doi.org/10.1056/NEJM199008233230803.CrossRefPubMed

34.

Hazenberg BP, van Rijswijk MH, Piers DA, Lub-de Hooge MN, Vellenga E, Haagsma EB, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med. 2006;119(4):355 e15–24. https://doi.org/10.1016/j.amjmed.2005.08.043.CrossRef

35.

Wall JS, Kennel SJ, Stuckey AC, Long MJ, Townsend DW, Smith GT, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010;116(13):2241–4. https://doi.org/10.1182/blood-2010-03-273797.CrossRefPubMedPubMedCentral

36.

Saido T, Leissring MA. Proteolytic degradation of amyloid beta-protein. Cold Spring Harb Perspect Med. 2012;2(6):a006379. https://doi.org/10.1101/cshperspect.a006379.CrossRefPubMedPubMedCentral

37.

Sojan SM, Smyth DR, Tsopelas C, Mudge D, Collins PJ, Chatterton BE. Pharmacokinetics and normal scintigraphic appearance of 99mTc aprotinin. Nucl Med Commun. 2005;26(6):535–9.CrossRefPubMed

38.

Han S, Chong V, Murray T, McDonagh T, Hunter J, Poon FW, et al. Preliminary experience of 99mTc-Aprotinin scintigraphy in amyloidosis. Eur J Haematol. 2007;79(6):494–500. https://doi.org/10.1111/j.1600-0609.2007.00963.x.CrossRefPubMed

39.

Kozak RW, Golker CF, Stadler P. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective. Dev Biol Stand. 1996;88:257–64.PubMed

40.

Lekakis J, Dimopoulos M, Nanas J, Prassopoulos V, Agapitos N, Alexopoulos G, et al. Antimyosin scintigraphy for detection of cardiac amyloidosis. Am J Cardiol. 1997;80(7):963–5.CrossRefPubMed

41.

Coutinho MC, Cortez-Dias N, Cantinho G, Conceicao I, Oliveira A, Bordalo e Sa A, et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging. 2013;6(5):627–36. https://doi.org/10.1161/CIRCIMAGING.112.000367.CrossRefPubMed

42.

Chen W, Cao Q, Dilsizian V. Variation of heart-to-mediastinal ratio in (123)I-mIBG cardiac sympathetic imaging: its affecting factors and potential corrections. Curr Cardiol Rep. 2011;13(2):132–7. https://doi.org/10.1007/s11886-010-0157-y.CrossRefPubMed

Titel: Molecular Imaging of Cardiac Amyloidosis
verfasst von: Sarah Cuddy
Rodney Falk
Sharmila Dorbala
Publikationsdatum: 01.07.2018
Verlag: Springer US
Erschienen in: Current Cardiovascular Imaging Reports / Ausgabe 7/2018
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-018-9457-1

Neu im Fachgebiet Kardiologie

16.04.2024 | Chronische Herzinsuffizienz | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Molecular Imaging of Cardiac Amyloidosis

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Selbstexpandierende TAVI-Klappen bei kleinem Aortenanulus im Vorteil

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Update Kardiologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Kardiologie

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Selbstexpandierende TAVI-Klappen bei kleinem Aortenanulus im Vorteil

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Update Kardiologie